Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, which is in Phase II clinical trial for treating atopic dermatitis and allergic asthma; FB704A which is in Phase II clinical trial for the treatment of rheumatoid arthritis and inhibiting tumor angiogenesis; SNS812, which is in Phase II clinical trial for the treatment of COVID; and SNS851 which is in clinical development for potential applications in metabolic diseases such as obesity, diabetes, hypercholesterolemia, and fatty liver disease. In addition, the company is involved in the management of agriculture cultivation and organic food trading business; and sale of organic food, dietary supplements, and beverages. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.
Frequently asked questions
What sector does Oneness Biotech Co Ltd (4743) operate in?
Oneness Biotech Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Oneness Biotech Co Ltd (4743) current stock price?
As of the latest data, Oneness Biotech Co Ltd stock price is NT$47.95, with a previous close of NT$47.95.
What is Oneness Biotech Co Ltd (4743) current market capitalization?
Oneness Biotech Co Ltd market cap is approximately 22.99 billion.
What is Oneness Biotech Co Ltd (4743) Earnings Per Share (EPS)?
The trailing EPS is -NT$2.15.
Does Oneness Biotech Co Ltd (4743) pay dividends?
No. Oneness Biotech Co Ltd does not pay a dividend.
What is Oneness Biotech Co Ltd (4743) beta (volatility) score?
Oneness Biotech Co Ltd has a beta of 0.733, indicating lower volatility than the overall market.
